HEALTHVTDIGGER
UVM Health to suspend weight loss drug coverage for its employees
UVM Health plans to stop covering weight loss medications for employees starting September 2023, aiming to save $19 million annually. The decision affects GLP-1 drugs like Ozempic and Zepbound, which are costly out-of-pocket for employees, while coverage for diabetes treatment remains. Employees express concern over financial burden and health impacts.
Mentioned
Related Signal
Adjacent reporting
- Some U.S. employers are dropping weight loss drug coverage as use surges
- STAT+: Pharmalittle: We’re reading about employer coverage of obesity drugs, another Sanofi setback, and more
- Trouble Getting Weight Loss Drugs Covered by Insurance? Here’s What To Know
- Insurance increasingly dropping weight loss drugs like Wegovy, Zepbound
- US states drop Medicaid coverage of GLP-1 weight-loss drugs as demand rises
- This CEO wants to cover weight loss drugs for employees. They're just too expensive.